Download MendeleyA conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity.
Boeszoermenyi, A., Bernaleau, L., Chen, X., Kartnig, F., Xie, M., Zhang, H., Zhang, S., Delacretaz, M., Koren, A., Hopp, A.K., Dvorak, V., Kubicek, S., Aletaha, D., Yang, M., Rebsamen, M., Heinz, L.X., Superti-Furga, G.(2023) Nat Commun 14: 6626-6626
- PubMed: 37863876 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41467-023-42070-3
- Primary Citation Related Structures:
8JZX - PubMed Abstract:
Dysregulation of pathogen-recognition pathways of the innate immune system is associated with multiple autoimmune disorders. Due to the intricacies of the molecular network involved, the identification of pathway- and disease-specific therapeutics has been challenging. Using a phenotypic assay monitoring the degradation of the immune adapter TASL, we identify feeblin, a chemical entity which inhibits the nucleic acid-sensing TLR7/8 pathway activating IRF5 by disrupting the SLC15A4-TASL adapter module. A high-resolution cryo-EM structure of feeblin with SLC15A4 reveals that the inhibitor binds a lysosomal outward-open conformation incompatible with TASL binding on the cytoplasmic side, leading to degradation of TASL. This mechanism of action exploits a conformational switch and converts a target-binding event into proteostatic regulation of the effector protein TASL, interrupting the TLR7/8-IRF5 signaling pathway and preventing downstream proinflammatory responses. Considering that all components involved have been genetically associated with systemic lupus erythematosus and that feeblin blocks responses in disease-relevant human immune cells from patients, the study represents a proof-of-concept for the development of therapeutics against this disease.
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Organizational Affiliation:
